rss
Thorax 1999;54:488-492 doi:10.1136/thx.54.6.488
  • Original article

Effects of inhaled β agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma

  1. Robert J Hancoxa,
  2. David A Stevensb,
  3. Ian M Adcockb,
  4. Peter J Barnesb,
  5. D Robin Taylora
  1. aDepartment of Respiratory Medicine, Dunedin School of Medicine, University of Otago, New Zealand, bNational Heart & Lung Institute, London SW3 6LY, UK
  1. Dr D R Taylor, Department of Medicine, Dunedin School of Medicine, PO Box 913, Dunedin, New Zealand.
  • Received 2 March 1998
  • Revision requested 25 August 1998
  • Revised 11 February 1999
  • Accepted 11 February 1999

Abstract

BACKGROUND Inhaled corticosteroids and β agonists are the most commonly used treatments in asthma and are often used together. Recent evidence suggests that many of the anti-inflammatory actions of corticosteroids are mediated by cross-talk between the activated glucocorticoid receptor (GR) and other transcription factors such as the pro-inflammatory nuclear factor kappa B (NFκB). Beta agonists can activate the transcription factor cAMP response element binding protein (CREB). A mutual inhibition between GR and CREB occurs in vitro which raises the possibility of a negative interaction between corticosteroid and β agonist drugs. A study was undertaken to determine whether these interactions occur during treatment with β2 agonists and corticosteroids in asthma.

METHODS Seven subjects who were participating in a randomised, placebo controlled, crossover study of six weeks treatment with inhaled budesonide (400 μg twice daily), terbutaline (1 mg four times daily), and combined treatment were recruited. Biopsy samples of the bronchial mucosa were obtained after each treatment and analysed for the DNA binding activity of GR, CREB, and NFκB.

RESULTS Budesonide increased GR activity (p<0.05) and decreased NFκB activity (p<0.05). No treatment combination altered CREB activity and terbutaline had no significant effects on any transcription factor.

CONCLUSIONS Inhaled corticosteroids have significant effects on GR and NFκB activity in bronchial mucosa. A negative interaction between inhaled corticosteroids and β agonists was not found.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.